Iovance Biotherapeutics, Inc. (1IOVA)
MTA
Closed
Aug 25, 2026
Day's Range
6.8952 wk Range
1.51Overview - 1IOVA - Iovance Biotherapeutics, Inc.
Key Statistics
Valuation
Enterprise Value
2.51B
P/E (Trailing)
‪-6.65‬
PEG Ratio
‪0.09‬
Price / Sales (TTM)
‪9.57‬
Price / Book
‪4.93‬
EV / EBITDA
‪-11.29‬
Profitability
Gross Margin
‪56.10%‬
Profit Margin
‪-89.09%‬
Operating Margin
‪-52.26%‬
Return on Assets
‪-20.30%‬
Return on Equity
‪-40.36%‬
Ownership
Shares Outstanding
452.97M
Float
394.36M
Held by Insiders
‪0.34%‬
Held by Institutions
‪70.50%‬
Price stats
Beta
‪0.70‬
50-Day Avg
‪4.35‬
200-Day Avg
‪3.13‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - 1IOVA - Iovance Biotherapeutics, Inc.
Peers - 1IOVA - Iovance Biotherapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on MTA.
- 1IOVAMTAIovance Biotherapeutics, Inc.885.23MMarket Cap+64.75%52-week change-6.00P/E (Trailing)‪-89.09%‬Profit Margin
- 1VRTXMTAVertex Pharmaceuticals Incorporated107.27BMarket Cap+27.82%52-week change32.13P/E (Trailing)‪34.99%‬Profit Margin
- 1REGNMTARegeneron Pharmaceuticals Inc.73.52BMarket Cap+27.69%52-week change20.61P/E (Trailing)‪27.86%‬Profit Margin
- 1ALNYMTAAlnylam Pharmaceuticals Inc45.81BMarket Cap-89.61%52-week change41.96P/E (Trailing)‪16.12%‬Profit Margin
- 1ALABMTAASTERA LABS INC COMMON STOCK (Ticker: 1ALAB)41.80BMarket Cap+44.44%52-week change137.71P/E (Trailing)‪30.74%‬Profit Margin
- 1INSMMTAInsmed Inc30.28BMarket Cap+16.20%52-week change-17.19P/E (Trailing)‪-76.94%‬Profit Margin
- 1CGMTAThe Carlyle Group Inc.18.64BMarket Cap-16.74%52-week change50.83P/E (Trailing)‪13.01%‬Profit Margin
Profile Summary - 1IOVA - Iovance Biotherapeutics, Inc.
About
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company pioneering the development and commercialization of tumor-infiltrating lymphocyte (TIL) cell therapies for patients with solid tumor cancers. The company's approach harnesses the immune system's natural ability to recognize and attack cancer cells…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
